Patient characteristics at time of 17p− documentation
| Characteristic . | M. D. Anderson (n = 64) . | Mayo Clinic (n = 35) . | P . |
|---|---|---|---|
| Median survivor follow-up after 17p− documentation, mos (range) | 28 (7-60) | 28 (1-70) | NA |
| Median age, y (range) | 61 (40-84) | 69 (45-87) | .03 |
| Age ≥ 60 y, n (%) | 34 (53) | 25 (71) | NS |
| Male sex, n (%) | 39 (61) | 20 (57) | NS |
| Median months since diagnosis (range) | 9 (0–142) | 13 (0–313) | NS |
| Performance status ECOG 1 or higher, n (%) | 31 (48) | 6 (17) | .002 |
| B-symptoms, n (%) | 13 (20) | 3 (9) | NS |
| Rai stage 0, n (%) | 18 (28) | 15 (43) | NS |
| Rai stage 1 or 2, n (%) | 32 (50) | 16 (46) | NS |
| Rai stage 3 or 4, n (%) | 14 (22) | 4 (11) | NS |
| Median white cell count, ×109/L (range) | 44 (6-281) | 19 (8-150) | .002 |
| β2m ≥ 2 × upper limit of normal, n (%) | 26 (41) | 8 (40) | NS |
| Median FISH 17p deletion % (range) | 46 (8-97) | 64 (10-96) | .05 |
| FISH 17p deletion < 25%, n (%) | 21 (33) | 7 (20) | NS |
| FISH 17p deletion 25%-49%, n (%) | 11 (17) | 5 (14) | NS |
| FISH 17p deletion 50%-74%, n (%) | 10 (16) | 8 (23) | NS |
| FISH 17p deletion ≥ 75%, n (%) | 22 (34) | 15 (43) | NS |
| FISH 17p deletion only, n (%) | 25 (39) | 6 (17) | NS |
| FISH 11q deletion in addition, n (%)* | 9 (14) | 8 (23) | NS |
| FISH trisomy 12 in addition, n (%)* | 7 (11) | 3 (9) | NS |
| FISH 13q deletion in addition, n (%)* | 23 (36) | 18 (51) | NS |
| Abnormal 17p on karyotype, n (%) | 23 (40) | 1 (25) | NS |
| CD38+†, n (%) | 17 (29) | 13 (35) | NS |
| ZAP-70+†, n (%) | 19 (58) | 11 (39) | NS |
| Unmutated IgVH, n (%) | 39 (70) | 15 (57) | NS |
| Commenced CLL therapy, n (%) | 46 (72)‡ | 11 (31)‡ | <.001 |
| First CLL therapy type, n (%) | |||
| Rituximab without chemotherapy | 5 (11) | 1 (9) | NA |
| PA + rituximab based | 22 (48) | 3 (27) | NA |
| PA, alemtuzumab, + rituximab based | 14 (30) | 2 (18) | NA |
| Other | 5 (11) | 5 (45) | NA |
| Characteristic . | M. D. Anderson (n = 64) . | Mayo Clinic (n = 35) . | P . |
|---|---|---|---|
| Median survivor follow-up after 17p− documentation, mos (range) | 28 (7-60) | 28 (1-70) | NA |
| Median age, y (range) | 61 (40-84) | 69 (45-87) | .03 |
| Age ≥ 60 y, n (%) | 34 (53) | 25 (71) | NS |
| Male sex, n (%) | 39 (61) | 20 (57) | NS |
| Median months since diagnosis (range) | 9 (0–142) | 13 (0–313) | NS |
| Performance status ECOG 1 or higher, n (%) | 31 (48) | 6 (17) | .002 |
| B-symptoms, n (%) | 13 (20) | 3 (9) | NS |
| Rai stage 0, n (%) | 18 (28) | 15 (43) | NS |
| Rai stage 1 or 2, n (%) | 32 (50) | 16 (46) | NS |
| Rai stage 3 or 4, n (%) | 14 (22) | 4 (11) | NS |
| Median white cell count, ×109/L (range) | 44 (6-281) | 19 (8-150) | .002 |
| β2m ≥ 2 × upper limit of normal, n (%) | 26 (41) | 8 (40) | NS |
| Median FISH 17p deletion % (range) | 46 (8-97) | 64 (10-96) | .05 |
| FISH 17p deletion < 25%, n (%) | 21 (33) | 7 (20) | NS |
| FISH 17p deletion 25%-49%, n (%) | 11 (17) | 5 (14) | NS |
| FISH 17p deletion 50%-74%, n (%) | 10 (16) | 8 (23) | NS |
| FISH 17p deletion ≥ 75%, n (%) | 22 (34) | 15 (43) | NS |
| FISH 17p deletion only, n (%) | 25 (39) | 6 (17) | NS |
| FISH 11q deletion in addition, n (%)* | 9 (14) | 8 (23) | NS |
| FISH trisomy 12 in addition, n (%)* | 7 (11) | 3 (9) | NS |
| FISH 13q deletion in addition, n (%)* | 23 (36) | 18 (51) | NS |
| Abnormal 17p on karyotype, n (%) | 23 (40) | 1 (25) | NS |
| CD38+†, n (%) | 17 (29) | 13 (35) | NS |
| ZAP-70+†, n (%) | 19 (58) | 11 (39) | NS |
| Unmutated IgVH, n (%) | 39 (70) | 15 (57) | NS |
| Commenced CLL therapy, n (%) | 46 (72)‡ | 11 (31)‡ | <.001 |
| First CLL therapy type, n (%) | |||
| Rituximab without chemotherapy | 5 (11) | 1 (9) | NA |
| PA + rituximab based | 22 (48) | 3 (27) | NA |
| PA, alemtuzumab, + rituximab based | 14 (30) | 2 (18) | NA |
| Other | 5 (11) | 5 (45) | NA |
Percentages were calculated based on the total number of patients with evaluable information. Therapies listed under “Other” were: for M.D. Anderson, lenalidomide (n = 4), and R-CHOP (n = 1); for the Mayo Clinic, chlorambucil (n = 1), pentostatin plus cyclophosphamide (n = 1), R-CVP (n = 2) and R-CHOP (n = 1).
ECOG indicates Eastern Cooperative Oncology Group; FISH, fluorescent in situ hybridization; CLL, chronic lymphocytic leukemia; PA, purine analogue; NA, not applicable; and NS, not significant.
Patients were ranked in the hierarchical classification proposed by Dohner et al.2 For example, a patient with concomitant deletions of 11q and 13q would be classified as having 11q deletion.
Defined as ≥ 30% for CD38 and ≥ 20% for ZAP-70.
Excluding patients enrolled in early intervention trials for disease not meeting National Cancer Institute Working Group treatment criteria.